{"id":52286,"date":"2022-12-22T15:02:15","date_gmt":"2022-12-22T14:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/"},"modified":"2022-12-22T15:02:15","modified_gmt":"2022-12-22T14:02:15","slug":"pavmed-partners-with-novosound-on-ultrasound-imaging-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/","title":{"rendered":"PAVmed Partners with Novosound on Ultrasound Imaging Technology"},"content":{"rendered":"
\n

\nLicense option and joint R&D agreement seek to apply Novosound\u2019s groundbreaking flexible thin-film ultrasound technology to intravascular imaging<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–$PAVM<\/a> #CarpX<\/a>—PAVmed Inc.<\/b><\/a> (Nasdaq: PAVM, PAVMZ<\/b>) (\u201cPAVmed\u201d), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. (\u201cNovosound\u201d), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound\u2019s proprietary flexible thin-film ultrasound technology in medical imaging, initially targeting next-generation intravascular ultrasound (IVUS) imaging.\n<\/p>\n

<\/a><\/p>\n

\n\u201cNearly all of the advances in ultrasound imaging technology over the past several decades have focused on leveraging an explosion of computational power for digital image processing, along with novel configurations of otherwise decades-old, rigid, machined ceramic, piezoelectric sensors,\u201d said Lishan Aklog, M.D.<\/a>, PAVmed\u2019s Chairman and Chief Executive Officer. \u201cThe Novosound team has developed groundbreaking technology whereby the piezoelectric material is lithographically \u2018printed\u2019 on a flexible thin-film substrate and have proven the technology\u2019s applicability in a commercially successful industrial application.\u201d\n<\/p>\n

\n\u201cWe believe Novosound\u2019s technology, which overcomes many of the limitations of conventional ultrasound, including the cost of high-frequency, high-resolution imaging, has the potential to be a once-in-a-generation breakthrough in ultrasonic medical imaging,\u201d Dr. Aklog added. \u201cWe are excited to join forces with Novosound to explore applying their technology in medical imaging, initially targeting the intravascular ultrasound catheter market. This partnership is a testament to our ongoing commitment to seek out and make modest investments in innovative technologies with large market opportunities while continuing to drive commercialization of our Lucid and Veris product lines.\u201d\n<\/p>\n

\n\u201cThe PAVmed team has a strong track record of innovation and delivering commercial-stage medical technologies,\u201d said Dave Hughes, Chief Executive Officer and co-founder of Novosound. \u201cThey are the ideal partners for Novosound as we increasingly gain traction in the international healthcare sector.\u201d\n<\/p>\n

\nUnder the terms of the agreement, PAVmed and Novosound will collaborate on a joint research and development project to establish that Novosound\u2019s proprietary technology can be incorporated into an intravascular ultrasound catheter, producing cross-sectional images of vascular structures using high-resolution, low-cost, miniaturized ultrasound two-dimensional arrays without the mechanical rotation of sensors that IVUS catheters have historically required. Upon achievement of certain development milestones, PAVmed will have the option to license Novosound\u2019s technology for use in the commercialization of intravascular imaging products. Target specifications include order of magnitude improvements in image resolution and sensor manufacturing costs, offering the potential for a disposable product. PAVmed and Novosound already have an active partnership that seeks to apply Novosound\u2019s ultrasound technology to PAVmed\u2019s CarpX\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome.\n<\/p>\n

\nAbout PAVmed<\/b>\n<\/p>\n

\nPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard\u00ae<\/sup> Esophageal DNA Test and EsoCheck\u00ae<\/sup> Esophageal Cell Collection Device\u2014the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. PAVmed\u2019s other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. PAVmed\u2019s product pipeline also includes the CarpX\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome, EsoCure\u2122 Esophageal Ablation Device with Caldus\u2122 Technology, and PortIO\u2122 Implantable Intraosseous Vascular Access Device, as well as other earlier-stage technologies. For more information on PAVmed, please visit PAVmed.com<\/a> and follow PAVmed on Twitter<\/a>, LinkedIn<\/a>, and YouTube<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed\u2019s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed\u2019s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed\u2019s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed\u2019s clinical and preclinical studies; whether and when PAVmed\u2019s products are cleared by regulatory authorities; market acceptance of PAVmed\u2019s products once cleared and commercialized; PAVmed\u2019s ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic\u2019s impact on PAVmed\u2019s businesses. PAVmed expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on PAVmed\u2019s businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed\u2019s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed\u2019s future operations, see Part I, Item 1A, \u201cRisk Factors,\u201d in PAVmed\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \u201cRisk Factors\u201d in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors and Media
\n
\n<\/span>
Adrian K. Miller
\n
PAVmed Inc.
\n
AKM@PAVmed.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

License option and joint R&D agreement seek to apply Novosound\u2019s groundbreaking flexible thin-film ultrasound technology to intravascular imaging NEW YORK–(BUSINESS WIRE)–$PAVM #CarpX—PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-52286","format-standard","category-industry"],"yoast_head":"\nPAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"License option and joint R&D agreement seek to apply Novosound\u2019s groundbreaking flexible thin-film ultrasound technology to intravascular imaging NEW YORK–(BUSINESS WIRE)–$PAVM #CarpX—PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-22T14:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PAVmed Partners with Novosound on Ultrasound Imaging Technology\",\"datePublished\":\"2022-12-22T14:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/\"},\"wordCount\":1007,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005270\\\/en\\\/1671749\\\/21\\\/PAVM_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/\",\"name\":\"PAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005270\\\/en\\\/1671749\\\/21\\\/PAVM_Logo.jpg\",\"datePublished\":\"2022-12-22T14:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005270\\\/en\\\/1671749\\\/21\\\/PAVM_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005270\\\/en\\\/1671749\\\/21\\\/PAVM_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PAVmed Partners with Novosound on Ultrasound Imaging Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/","og_locale":"en_US","og_type":"article","og_title":"PAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend","og_description":"License option and joint R&D agreement seek to apply Novosound\u2019s groundbreaking flexible thin-film ultrasound technology to intravascular imaging NEW YORK–(BUSINESS WIRE)–$PAVM #CarpX—PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-22T14:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PAVmed Partners with Novosound on Ultrasound Imaging Technology","datePublished":"2022-12-22T14:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/"},"wordCount":1007,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/","url":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/","name":"PAVmed Partners with Novosound on Ultrasound Imaging Technology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg","datePublished":"2022-12-22T14:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221222005270\/en\/1671749\/21\/PAVM_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pavmed-partners-with-novosound-on-ultrasound-imaging-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PAVmed Partners with Novosound on Ultrasound Imaging Technology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52286"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52286\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}